Quality Assurance in Ovarian Cancer (QS-OVAR)

Quality Assurance in Ovarian Cancer (QS-OVAR) - QS-OVAR 2021

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027253

Enrollment

1000

Registered

2021-12-07

Start date

2022-08-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C56

Interventions

Group 1: The subject of this voluntary quality assurance measure is the nationwide collection of data on of the surgical steps and systemic treatments used (chemotherapies and targeted therapies) in c

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Age at least 18 years - Date of primary diagnosis in Q3/2021 - Invasive epithelial ovarian cancer, fallopian tube or peritoneal cancer

Exclusion criteria

Exclusion criteria: - Borderline tumours - other non-epithelial ovarian malignancies (germ cell tumours, stromal cell tumours, sarcomas)

Design outcomes

Primary

Measure	Time frame
Overall Survival	—

Secondary

Measure	Time frame
Success of Surgery Primary and Relapse chemotherapy as per the guidelines Relapse-free survival Survival following relapse Time from relapse to first and second subsequent treatments	—

Countries

Germany

Contacts

Public ContactMarkus Kerkmann

MMF GmbH

ovar@mmf-research.de0251-928730-17

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026